304 related articles for article (PubMed ID: 36536400)
1. Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.
Gao XM; Li J; Cao XX
Cell Commun Signal; 2022 Dec; 20(1):195. PubMed ID: 36536400
[TBL] [Abstract][Full Text] [Related]
2. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
Jouenne F; Benattia A; Tazi A
Curr Opin Oncol; 2021 Mar; 33(2):101-109. PubMed ID: 33315630
[TBL] [Abstract][Full Text] [Related]
3. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.
Hogstad B; Berres ML; Chakraborty R; Tang J; Bigenwald C; Serasinghe M; Lim KPH; Lin H; Man TK; Remark R; Baxter S; Kana V; Jordan S; Karoulia Z; Kwan WH; Leboeuf M; Brandt E; Salmon H; McClain K; Poulikakos P; Chipuk J; Mulder WJM; Allen CE; Merad M
J Exp Med; 2018 Jan; 215(1):319-336. PubMed ID: 29263218
[TBL] [Abstract][Full Text] [Related]
4. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
5. Success of Trametinib in the Treatment of Langerhans Cell Histiocytosis With Novel MAPK Pathway Mutations.
Orr K; Hustak S; Beaudoin R; Ray A
J Pediatr Hematol Oncol; 2023 May; 45(4):e534-e538. PubMed ID: 36730444
[TBL] [Abstract][Full Text] [Related]
6. Langerhans cell histiocytosis: current advances in molecular pathogenesis.
Sconocchia T; Foßelteder J; Sconocchia G; Reinisch A
Front Immunol; 2023; 14():1275085. PubMed ID: 37965340
[TBL] [Abstract][Full Text] [Related]
7. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
[TBL] [Abstract][Full Text] [Related]
8. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
Kobayashi M; Tojo A
Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
[TBL] [Abstract][Full Text] [Related]
9. Langerhans cell histiocytosis.
Rodriguez-Galindo C; Allen CE
Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
[TBL] [Abstract][Full Text] [Related]
10. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
11. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
[TBL] [Abstract][Full Text] [Related]
12. [Progress in the Treatment of Adult Langerhans Cell Histiocytosis --Review].
Tian ZZ; Cui YJ; Peng HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):970-974. PubMed ID: 35680836
[TBL] [Abstract][Full Text] [Related]
13. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
15. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
[TBL] [Abstract][Full Text] [Related]
16. Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.
Bahabri A; Abla O
Expert Rev Hematol; 2024 Jun; 17(6):223-231. PubMed ID: 38721670
[TBL] [Abstract][Full Text] [Related]
17. Somatic activating ARAF mutations in Langerhans cell histiocytosis.
Nelson DS; Quispel W; Badalian-Very G; van Halteren AG; van den Bos C; Bovée JV; Tian SY; Van Hummelen P; Ducar M; MacConaill LE; Egeler RM; Rollins BJ
Blood; 2014 May; 123(20):3152-5. PubMed ID: 24652991
[TBL] [Abstract][Full Text] [Related]
18. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
19. Langerhans cell histiocytosis: Version 2021.
Gulati N; Allen CE
Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):15-23. PubMed ID: 34105821
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
